Medicare Semaglutide Coverage: Millions May Gain Access That Could Cost $145 Billion
August 26th 2024Medicare has not clearly defined what constitutes "established cardiovascular disease," leading to variability in potential patient eligibility; therefore, researchers aimed to estimate the number of Medicare beneficiaries who would become newly eligible for semaglutide under different definitions.
Read More
Dr Martha Gulati Previews ESC 2024: Obesity, Heart Failure, and the Ongoing Debate on HRT
August 26th 2024Martha Gulati, MD, Cedars-Sinai, discusses the topics expected to be featured at the European Society of Cardiology (ESC) Congress, including a debate she's participating in about the role of hormone replacement therapy (HRT) in primary cardiovascular disease prevention.
Watch
The Persistent, and Rising, Threat of Black Lung Disease
August 26th 2024Also known as coal workers’ pneumoconiosis, black lung disease (or miner’s lung) is typically the result of inhaling coal dust for many years that causes scarring in the lungs and makes breathing increasingly difficult. The prevalence of black lung has been on the rise in the US.
Read More
Biosimilar Updates: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results
August 25th 2024Celltrion's adalimumab-aaty biosimilar is now accessible for all Costco members, while Amgen sues Samsung Bioepis over the latter’s denosumab biosimilar candidate, and GlycoNex progresses its denosumab biosimilar SPD8 to phase 3 trials.
Read More
New CAR T Trial in MM Aims for Triple Receptor Targeting
August 24th 2024Leland Metheny, MD, is lead investigator for the Phase 1 BAFF CAR T clinical trial, which is evaluating the safety and effectiveness of a novel approach to chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) that targets 3 receptors on cancer cells and uses electroporation vs the typical lentiviral vector delivery.
Watch
No Sex-Based Differences Found in Treatment Timing in gMG
August 24th 2024A single-center cohort study found no differences between males and females in the odds of starting or time to treatment in generalized myasthenia gravis (gMG), but investigators want to continue to probe more deeply into why women are more severely affected by the disease.
Read More
CPAP Treatment Can Significantly Reduce Hypertensive Adverse Outcomes in Pregnancy
August 24th 2024When women with obstructive sleep apnea (OSA) carrying high-risk pregnancies collaborate with their health care providers to find the best individualized continuous positive airway pressure (CPAP) treatment, their risks of gestational hypertension and preeclampsia may drop appreciably
Read More
Health Equity & Access Weekly Roundup: August 24, 2024
August 24th 2024Learn more about the negotiated Medicare drug prices and what the FDA's rejection of therapeutic MDMA means for mental health care through expert reactions. Other highlights include pharmacy-based HIV care, gaps in care for gastrointestinal stromal tumors, and the obesity epidemic.
Read More
Postdischarge Mortality Remains Unchanged Despite Advances in Heart Failure Care
August 23rd 2024Heart failure mortality rates after hospital discharge have seen little improvement since 2010 among Medicare beneficiaries, with real-world outcomes falling short of clinical trial expectations.
Read More
Alopecia Areata Linked to Autoimmune, Psychiatric Risks
August 23rd 2024Patients with alopecia areata have a significantly increased risk of developing psychiatric and autoimmune diseases both before and after diagnosis, highlighting the importance of comprehensive care for these individuals.
Read More
Beyond Early Stage: Biomarker Testing's Role in Advanced Lung Cancer
August 23rd 2024In part 1 of our interview with David P. Carbone, MD, PhD, The Ohio State University, he addressed why it is important to conduct biomarker testing in both lung cancer overall and non–small cell lung cancer more specifically.
Read More
SMN Depletion May Increase Risk of Liver Damage, Fatty Liver in SMA
August 22nd 2024A retrospective, single-center cohort study utilized liver ultrasound, serum collection, and proteome analysis to draw associations between spinal motor neuron (SMN) protein depletion and heightened risk for fatty liver disease in spinal muscular atrophy (SMA).
Read More